You are here: Industry Insights > Opdivo

News List

EC Approval for Opdivo Plus Yervoy as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma americanpharmaceuticalreview
June 04, 2021
Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adults with unresectable malignant pleural mesothelioma (MPM).
Opdivo plus Yervoy moves closer to EU approval for dMMR/MSI-H colorectal cancer pharmatimes
May 26, 2021
Bristol Myers Squibb’s (BMS) Opdivo plus Yervoy combination therapy has moved closer to EU approval for certain colorectal cancer patients, after scoring a positive opinion from the European Medicines Agency’s (EMA) Committee for ...
BMS’ Opdivo/Yervoy improves long-term survival for melanoma patients pharmatimes
May 25, 2021
Bristol Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab) combination has demonstrated ‘durable improvement in survival’, according to new long-term data from a Phase III trial.
NICE nod for BMS’ Opdivo in advanced oesophageal cancer pharmatimes
May 17, 2021
The UK National Institute for Health and Care Excellence (NICE) has recommended Bristol Myers Squibb’s (BMS) Opdivo for the treatment of unresectable advanced oesophageal squamous cell cancer (OSCC).
NICE 'no' for Opdivo/Yervoy lung cancer combo pharmatimes
April 13, 2021
The National Institute for Health and Care Excellence (NICE) has issued a preliminary no for NHS use of Bristol-Myers Squibb's Opdivo (nivolumab)/Yervoy (ipilimumab) combination for treating a certain lung cancer.
Opdivo plus Cabometyx approved in the EU for advanced renal cancer pharmatimes
April 01, 2021
The European Commission (EC) has authorised Bristol Myers Squibb’s (BMS) Opdivo plus Ipsen’s Cabometyx as a first-line treatment for advanced renal cell carcinoma (aRCC).
BMS’ Opdivo plus LAG-3 antibody relatlimab show promise in melanoma pharmatimes
March 31, 2021
Bristol Myers Squibb (BMS) has revealed top-line data from a Phase II/III trial evaluating its PD-1 inhibitor Opdivo plus its investigational anti-LAG-3 antibody relatlimab in previously untreated metastatic or unresectable melanoma.
Compugen Expands Collaboration with Bristol Myers Squibb in COM701, Opdivo Study americanpharmaceuticalreview
February 26, 2021
Compugen announced the expansion of its clinical collaboration agreement with Bristol Myers Squibb. Under the amended agreement, Bristol Myers Squibb will supply Opdivo® (nivolumab), its PD-1 inhibitor, for Compugen's Phase 1b cohort expansion study ...
NICE no for BMS’ Opdivo for head and neck cancer pharmatimes
January 11, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has turned down Bristol Myers Squibb’s (BMS) immunotherapy Opdivo (nivolumab) for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) after platinum-based ...
Stellar Results from Kintor's GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40% prnasia
December 10, 2020
On December 9, 2020, Kintor Pharmaceutical Limited is pleased to announce that the Group has collected positive data in phase II clinical trials of combination therapy of ALK-1 (GT90001) antibody and PD-1 (Nivolumab or Opdivo) antibody for the second ...

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page